Clinical Trial Search

Primary: Change From Baseline in Participant's Self-Assessment of Severity of Vaginal Dryness to Week 12/Final Visit — 2.49; 2.46; 2.50; 2.50 score on a scale

Primary: Radiographic Progression-free Survival (rPFS) — 8.7; 3.4 Months — p=< 0.001

Primary: Number of Participants With Endometrial Biopsy Results at Final Visit — 3; 10; 7; 166 Participants

Primary: Number of Patients With a Major Cardiac Implantable Electronic Devices (CIED) Infection — 5; 6 Participants

Primary: Change From Baseline in Participant's Self-Assessment of Symptom of Vulvovaginal Atrophy (VVA): Dyspareunia (Pain Associated With Sexual Activity) to Final Assessment…

Primary: Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) During Treatment With Ribociclib + Letrozole in the Core Phase — 3203; 2461; 3091; 2192…

Primary: Maximum Observed Serum Concentration (Cmax) Of Ravulizumab — 725.40; 884.63; 1161.60; 1612.50 μg/mL

Primary: Change From Baseline in Participant's Self-Assessment of Severity of Vaginal Dryness to Final Assessment — 2.5; 2.5; -1.2; -1.4 score on a scale

Primary: Proportion of Participants With Absence of Active ROP and Unfavorable Structural Outcomes — 0.855; 0.821 Proportion of participants

Primary: Visual Analog Scale (VAS) — 1.29; 3.16; 2.89 score on a scale

Primary: Percent Change of Body Mass Index (BMI) as Calculated by the Formula: Body Weight in kg Divided by Height in Meters². — 1.7; 3.5 percent change from baseline — p=0.40

Primary: Number of Participants With Surgical Wound Infections From Surgery Through Post-operative Day 90 — 63; 65 Participants

Primary: Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48 — 6.6; 6.6 ETDRS Letters

Primary: Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48 — 5.8; 5.1 ETDRS Letters

Primary: Time From Cervical Ripening to Delivery — 16.88; 13.13 hours